CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Imfinzi for Non-Small Cell Lung Cancer – Details

Project Number PC0131-000
Brand Name Imfinzi
Generic Name Durvalumab
Strength 50 mg
Tumour Type Lung
Indication Non-Small Cell Lung Cancer
Funding Request For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) following curative intent platinum-based chemoradiation therapy, for up to a maximum of 12 months
Review Status Complete
Pre Noc Submission No
NOC Date May 4, 2018
Manufacturer AstraZeneca Canada
Sponsor AstraZeneca Canada
Submission Date September 21, 2018
Submission Deemed Complete October 5, 2018
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ October 5, 2018
Check-point meeting November 12, 2018
pERC Meeting February 21, 2019
Initial Recommendation Issued March 7, 2019
Feedback Deadline ‡ March 21, 2019
pERC Reconsideration Meeting April 18, 2019
Final Recommendation Issued May 3, 2019
Notification to Implement Issued May 21, 2019
Therapeutic Area Unresectable Non-Small Cell Lung Cancer (NSCLC)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.